Real‐world impact of a subsidy decision of sofosbuvir–velpatasvir for treatment of chronic hepatitis C on clinical practice and patient outcomes

BACKGROUND AND AIM: Sofosbuvir–velpatasvir was recommended for subsidy to treat chronic hepatitis C in Singapore in 2018. We measured the impact of the subsidy decision on clinical practice and patient outcomes. Specifically, we looked at pre‐ and post‐subsidy changes in the utilization and prescrib...

Descripción completa

Detalles Bibliográficos
Autores principales: Tan, Chee‐Kiat, Luo, Xue‐Shi, Ong, Benjamin Shao‐Kiat, Lin, Liang, Ng, Kwong‐Hoe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Publishing Asia Pty Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840192/
https://www.ncbi.nlm.nih.gov/pubmed/36660045
http://dx.doi.org/10.1002/jgh3.12850

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9840192/
https://www.ncbi.nlm.nih.gov/pubmed/36660045
http://dx.doi.org/10.1002/jgh3.12850

Ejemplares similares